Healthcare is also not an example of not regulating markets; rather, it's one of the most regulated markets in the USA. Some of the regulations are net-harmful, leading to problems like the gigantic prices of monopolized products.
I think you're mistaken about high prices for monopolized pharmaceuticals being a new phenomenon. Are you referring to the EpiPen, Daraprim, Alcortin A, Novacort, and Aloquin price hikes? But high prices are typical in monopolized pharmaceuticals. For example, Harvoni costs $32,000 in the USA, while its generic version costs $900 in India. This kind of price difference between the monopoly price and non-monopoly price is common.
All that aside, I agree that we can often do better than just not regulating industries. Much care should be taken to craft helpful regulations, and perhaps some kind of technology or institution can be developed to inhibit regulatory capture.